secwatch.observer — SEC 8-K summary
======================================

Issuer:     PharmaCyte Biotech, Inc. (PMCB)
CIK:        0001157075
Form:       8-K
Filed at:   2025-09-05T23:59:59+00:00
Accession:  0001683168-25-006727
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PharmaCyte Biotech invests $3M in TNF Pharma for convertible preferred and warrants linked to LightSolver license
--------------------------------------------------------------------------------

- PharmaCyte purchased $3M of TNF Series H convertible preferred shares (convertible at $5) and warrants for 600,000 common shares at $5 exercise price.
- Investment supports TNF's license with LightSolver for a light-speed computing platform for cryptocurrency mining and blockchain.
- TNF plans to change its name and ticker to reflect the new strategy; warrants expire 5 years after stockholder approval.
- Preferred shares carry 7% annual dividend (15% on trigger events) and price-based anti-dilution adjustments.
- PharmaCyte reports total assets over $55M as of April 30, 2025, and will use cash for this investment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157075/000168316825006727/0001683168-25-006727-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157075/000168316825006727/pharmacyte_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-25-006727

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer